RT Journal Article
SR Electronic
T1 PERFORMANCE EVALUATION OF A SARS-COV-2 RAPID ANTIGENTEST: TEST PERFORMANCE IN THE COMMUNITY IN THE NETHERLANDS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.19.20215202
DO 10.1101/2020.10.19.20215202
A1 N. Van der Moeren
A1 V.F. Zwart
A1 E.B. Lodder
A1 W. Van den Bijllaardt
A1 H.R.J.M. Van Esch
A1 J.J.J.M. Stohr
A1 J. Pot
A1 I. Welschen
A1 P.M.F. Van Mechelen
A1 S.D. Pas
A1 J.A.J.W. Kluytmans
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.19.20215202.abstract
AB Objectives This study was primarily conducted to evaluate clinical sensitivity and specificity of the SARS-CoV-2 rapid antigen test ‘BD Veritor System for Rapid Detection of SARS-CoV-2’ (VRD) compared to real time reverse transcriptase polymerase chain reaction (qRT-PCR). Furthermore, the VRD sensitivity for different Ct-value groups (Ct <20; Ct 20-25, Ct 25-30 and Ct ≥30) and different intervals since symptom onset (< 7 days; ≥ 7 days) were examined.Design Prospective performance evaluation study.Setting Municipal Health Service (GGD) COVID-19 test centres in West-Brabant, the NetherlandsParticipants In order to evaluate clinical specificity, 352 symptomatic adults (≥18 years) who presented at a participating GGD test centre for a COVID-19 test between September 28 and October 7 2020 were included. In order to evaluate clinical sensitivity, 123 symptomatic adults (≥18 years) who were tested positive with qRT-PCR in a participating GGD test centre between September 26 and October 6 were included.Results An overall clinical specificity of 100% (95%CI: 98.9%-100%) and sensitivity of 80.7% (95% CI: 73,2%-86,9%) was found for the VRD compared to qRT-PCR. Sensitivity was the highest for low Ct-value categories and for specimen obtained within the first days after disease onset. For specimen obtained within 7 days after onset of symptoms, the overall sensitivity was 91.0% (95% CI: 82,4%-96,3%) and 98,6% (95% CI: 92,3%-100%) for samples with qRT-PCR Ct-value beneath 30.Conclusion The VRD is a promising diagnostic test for COVID-19 community screening for symptomatic individuals within 7 days after symptom onset in function of disease control. The clinical sensitivity was highest when viral load was high, which correlated with the duration of symptoms. Further research on practical applicability and the optimal position of the test within the current testing landscape is needed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSubmitted at the Netherlands Trial Register (NTR), trial ID to be expected.Funding StatementBecton, Dickinson and Company was not actively involved in the design, execution, analysis or result interpretation of the study. The VRD tests for this study were provided by the Dutch Ministry of Health, Welfare and Sport (VWS). We want to thank the employees of the Microvida laboratory for Medical Microbiology at the Amphia Hospital Breda and the GGD West-Brabant for their substantial contribution to this study. Jan Kluytmans is member of the National Outbreak Management Team of The Netherlands and of a committee which supports the implementation of the Corona-reporting App. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical research Ethics Committees United Nieuwegein The NetherlandsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonimised crude data is present at the Microvida laboratory for Microbiology in Breda, The Netherlands and will be saved.